Moderna Stock

Moderna EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Moderna (MRNA) as of Aug 3, 2026 is -6.04. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was -3.17 — a change of 90.22% (lower).

EV/OCF

-6.04

YoY

90.22%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Moderna is 2026 -6.04 . EV/OCF (Enterprise Value to Operating Cash Flow) of Moderna was 2025 -3.17 . It decreases by 90.22% lower compared to the previous year.
Access this data via the Eulerpool API

Moderna Stock analysis

What does Moderna do? Moderna Inc is a biotechnology company from the USA that specializes in the development of therapies and vaccines based on mRNA technology. The company was founded in 2010 by a group of researchers led by Noubar Afeyan and is headquartered in Cambridge, Massachusetts. Moderna is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Moderna stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Moderna is -6.04 in 2026.

EV/OCF (Enterprise Value to Operating Cash Flow) of Moderna changed from -3.17 to -6.04, representing a 90.22% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Moderna since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Moderna with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Moderna

All Key Metrics — Moderna